Patterns of disease detection using [F-18]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial
Samantha Koschel, Kim Taubman, Thomas Sutherland, Kelvin Yap, Michael Chao, Mario Guerrieri, Angela Benson, Michelle Starmans, Graeme Byrne, Grace Ong, Craig Macleod, Marcus Foo, Lih Ming Wong, Dennis Gyomber, Michael Ng
European Journal of Nuclear Medicine and Molecular Imaging | SPRINGER | Published : 2021
PURPOSE: Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used in patients with biochemical recurrence post prostatectomy to detect local recurrence and metastatic disease at low PSA levels. The aim of this study was to assess patterns of disease detection, predictive factors and safety using [18F]DCFPyL PET/CT versus diagnostic CT in patients being considered for salvage radiotherapy with biochemical recurrence post prostatectomy. METHODS: We conducted a prospective trial recruiting 100 patients with detectable PSA post prostatectomy (PSA 0.2-2.0 ng/mL) and referred for salvage radiotherapy from August 2018 to July 2020. All patients underwent a PSMA PET/CT using the [18F]DC..View full abstract
Cyclotek (Aust) Pty Ltd. for their financial support via access to theirGMP-approved product, [18F]DCFPyL PSMAradiopharmaceutical, and through Cyclotek the support of the Australian Government as part of its CRC Projects Program.